(Q35878337)

10 August 2017

1 reference

title

Therapy of Helicobacter pylori (English)

1 reference

10 August 2017

0 references

Ramona McLoughlin

1

1 reference

10 August 2017

Istvan Racz

2

1 reference

10 August 2017

Martin Buckley

3

1 reference

10 August 2017

Humphrey J O'Connor

4

1 reference

10 August 2017

Colm O'Morain

5

1 reference

10 August 2017

publication date

1 January 2004

1 reference

10 August 2017

1 reference

10 August 2017

volume

9 Suppl 1

1 reference

10 August 2017

page(s)

42-48

1 reference

Current concepts in the management of Helicobacter pylori infection--the Maastricht 2-2000 Consensus Report

10 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1083-4389.2004.00251.X

Helicobacter pylori eradication and peptic ulcer healing: the impact of deleting the proton pump inhibitor and using a once-daily treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1083-4389.2004.00251.X

One-Day Quadruple Therapy Compared With 7-Day Triple Therapy for Helicobacter pylori Infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1083-4389.2004.00251.X

Three‐day intravenous triple therapy is not effective for the eradication of Helicobacter pyloriinfection in patients with bleeding gastro‐duodenal ulcer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1083-4389.2004.00251.X

Sequential treatment for Helicobacter pylori eradication in duodenal ulcer patients: improving the cost of pharmacotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1083-4389.2004.00251.X

Risk factors for failure of Helicobacter pylori therapy--results of an individual data analysis of 2751 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1083-4389.2004.00251.X

Sequential treatment for Helicobacter pylori does not share the risk factors of triple therapy failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1083-4389.2004.00251.X

Meta-analysis: comparative efficacy of different proton-pump inhibitors in triple therapy for Helicobacter pylori eradication

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1083-4389.2004.00251.X

Review article: the treatment of refractory Helicobacter pylori infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1083-4389.2004.00251.X

Prevalence of Helicobacter pylori resistance to clarithromycin and metronidazole determined by 23S ribosomal RNA and rdxA gene analyses in Hiroshima, Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1083-4389.2004.00251.X

Helicobacter pylori in children and adolescents: increase of primary clarithromycin resistance, 1997-2000.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1083-4389.2004.00251.X

The relationship among previous antimicrobial use, antimicrobial resistance, and treatment outcomes for Helicobacter pylori infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1083-4389.2004.00251.X

Efficacy of triple therapy comprising rabeprazole, amoxicillin and metronidazole for second-line Helicobacter pylori eradication in Japan, and the influence of metronidazole resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1083-4389.2004.00251.X

Role of antibiotic sensitivity testing before first-line Helicobacter pylori eradication treatments.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1083-4389.2004.00251.X

Is antimicrobial susceptibility testing necessary before second-line treatment for Helicobacter pylori infection?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1083-4389.2004.00251.X

Second‐line treatment for failure to eradicate Helicobacter pylori: a randomized trial comparing four treatment strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1083-4389.2004.00251.X

A third-line levofloxacin-based rescue therapy for Helicobacter pylori eradication

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1083-4389.2004.00251.X

Levofloxacin based triple therapy as a second-line treatment after failure of Helicobacter pylori eradication with standard triple therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1083-4389.2004.00251.X

'Rescue' therapy with rifabutin after multiple Helicobacter pylori treatment failures

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1083-4389.2004.00251.X

Effect of different doses of furazolidone with amoxicillin and omeprazole on eradication of Helicobacter pylori

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1083-4389.2004.00251.X

Beta-lactamase inhibitor enhances Helicobacter pylori eradication rate

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1083-4389.2004.00251.X

Use of lactoferrin for Helicobacter pylori eradication. Preliminary results

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1083-4389.2004.00251.X

Human recombinant lactoferrin is ineffective in the treatment of human Helicobacter pylori infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1083-4389.2004.00251.X

Favourable effect of regular intake of fermented milk containing Lactobacillus johnsonii on Helicobacter pylori associated gastritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1083-4389.2004.00251.X

Lactobacillus gasseri OLL2716 as a probiotic in clarithromycin-resistant Helicobacter pylori infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1083-4389.2004.00251.X

Inhibition of Helicobacter pylori growth in vitro by Bulgarian propolis: preliminary report

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1083-4389.2004.00251.X

Antimicrobial activity of essential oils against Helicobacter pylori.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1083-4389.2004.00251.X

Review article: the role of rebamipide in the management of inflammatory disease of the gastrointestinal tract

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1083-4389.2004.00251.X

Effects of rebamipide, a gastro-protective drug on the Helicobacter pylori status and inflammation in the gastric mucosa of patients with gastric ulcer: a randomized double-blind placebo-controlled multicentre trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1083-4389.2004.00251.X

A novel evaluation method of gastric mucoadhesive property in vitro and the mucoadhesive mechanism of tetracycline-sucralfate acidic complex for eradication of Helicobacter pylori

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1083-4389.2004.00251.X

Smoking and polymorphisms of fucosyltransferase gene Le affect success of H. pylori eradication with lansoprazole, amoxicillin, and clarithromycin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1083-4389.2004.00251.X

10.1111/J.1083-4389.2004.00251.X

21 January 2018

Identifiers

DOI

1 reference

10 August 2017

1 reference